Shugan Xiaozhi formula reduces hepatic steatosis and stiffness in MASLD patients with elevated ALT: An exploratory 24-week randomized trial
Pharmacological Research · 2026-12 · 234 · 109705
DOI: 10.1016/j.phrs.2026.109705 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pharmacological Research, 2026-12. Verfasst von Yuxin Sun und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medi…. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Clinical evidence supporting Shugan Xiaozhi Formula (SGXZ) for metabolic dysfunction-associated steatotic liver disease (MASLD) remains limited. This 24-week, multicenter, randomized, open-label exploratory trial compared SGXZ particles with vitamin E (300 mg daily) in 285 patients with MASLD and elevated ALT. The primary exploratory outcome measure was the change in liver steatosis and fibrosis severity. Secondary outcomes included liver enzyme levels, anthropometric data, and safety. The efficacy analysis included 152 subjects with evaluable 24-week results. Compared with vitamin E, in the SGXZ group, 22.4% of the subjects had a ≥1 grade decrease on MRI-PDFF in fat degeneration score, while in the vitamin E group it was only 5.3% (P = 0.007). In the SGXZ group, the CAP decreased by ≥30 dB/m in 82.9% compared to 39.5% in the vitamin E group (P 0.05). Compared with the control group, the weight (-2.69 kg), body mass index (-0.94 kg/m²), and waist-to-hip ratio (-0.04) in the SGXZ group decreased significantly (all P ≤ 0.020). These exploratory findings suggest that SGXZ may have potential benefits for MASLD, and it is worthy of further verification in larger-scale trials with more complete follow-up. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR2200057595.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, PR China.
- The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, PR China; Liuzhou Traditional Chinese Medicine Hospital, Liuzhou, Guangxi, PR China.
- Shenzhen Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Shenzhen, PR China.
- The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, PR China; Department of General Medicine, Longhua District People's Hospital, Shenzhen, PR China.
- The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, PR China.
- Dongguan Key Laboratory of Traditional Chinese Medicine Hepatology, the Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, PR China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, Y., Han, Z., Li, C., Hu, D., Xie, F., Li, Q., Luo, H., Liao, M., Zhou, X., Hu, J., Mo, S., Cai, N., Ma, X., Lai, Y., Zhang, S., Li, D., Xing, Y., Zhou, H., & Tong, G. (2026). Shugan Xiaozhi formula reduces hepatic steatosis and stiffness in MASLD patients with elevated ALT: An exploratory 24-week randomized trial. Pharmacological Research, 234, 109705. https://doi.org/10.1016/j.phrs.2026.109705
Vancouver
Sun Y, Han Z, Li C, Hu D, Xie F, Li Q, et al. Shugan Xiaozhi formula reduces hepatic steatosis and stiffness in MASLD patients with elevated ALT: An exploratory 24-week randomized trial. Pharmacological Research. 2026;234:109705. doi:10.1016/j.phrs.2026.109705
BibTeX
@article{Sun2026,
author = {Sun, Yuxin and Han, Zhiyi and Li, Can and Hu, Die and Xie, Fanci and Li, Qingqing and Luo, Hong and Liao, Mianmian and Zhou, Xiaoling and Hu, Jingbao and Mo, Shizao and Cai, Nailiang and Ma, Xiaojun and Lai, Yu and Zhang, Shijun and Li, Dan and Xing, Yufeng and Zhou, Hua and Tong, Guangdong},
title = {Shugan Xiaozhi formula reduces hepatic steatosis and stiffness in MASLD patients with elevated ALT: An exploratory 24-week randomized trial},
journal = {Pharmacological Research},
year = {2026},
volume = {234},
pages = {109705},
doi = {10.1016/j.phrs.2026.109705}
}
EUVIMED